A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: A genomic substudy of PACS01 clinical trial

Breast Cancer Research and Treatment

Volumn 116, Issue 3, 2009, Pages 509-520

  Jézéquel, Pascal ^a,b   Campone, Mario ^b   Roché, Henri ^c   Gouraud, Wilfried ^a,b,d   Charbonnel, Catherine ^a,b,d   Ricolleau, Gabriel ^b   Magrangeas, Florence ^a,d   Minvielle, Stéphane ^a,d   Genève, Jean ^e   Martin, Anne Laure ^e   Bataille, Régis ^b   Campion, Loïc ^b,d  

^a CHU de Nantes   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d INSTITUT DE BIOLOGIE   (France)

^e FNCLCC   (France)

Author keywords

Adjuvant chemotherapy; Breast cancer; Clinicogenomic model; FEC100 regimen; Genomic study; PACS01

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADJUVANT 38 GENE EXPRESSION SIGNATURE; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLASSIFICATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; HUMAN TISSUE; INTERLEUKIN 6 SIGNAL TRANSDUCER GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NOTTINGHAM PROGNOSTIC INDEX; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PHOSPHOGLYCERATE KINASE 1 GENE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHATASE 1 CATALYTIC SUBUNIT ALPHA ISOFORM GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SOLUTE CARRIER FAMILY 25 MEMBER 5 GENE; TRANSFORMING ACIDIC COILED COIL CONTAINING PROTEIN 3 GENE; TUBULIN BETA 2C GENE; TUBULIN BETA 3 GENE; UBIQUITIN CONJUGATING ENZYME E2C GENE; ADJUVANT CHEMOTHERAPY; AGED; BREAST TUMOR; DNA MICROARRAY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; GENETICS; LYMPH NODE; METABOLISM; METASTASIS; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CYCLOPHOSPHAMIDE; DOUBLE-BLIND METHOD; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MULTICENTER STUDIES AS TOPIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POSTMENOPAUSE; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70349578800     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0250-8     Document Type: Article

References (29)

1. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752. doi:10.1038/3502 1093
2. Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874. doi: 10.1073/pnas.191367098
3. Van't Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536. doi:10.1038/415530a
4. Van de Vijver MJ, He YD, van't Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009. doi:10.1056/NEJMoa021967
5. Wang Y, Klijn JGM, Zhang Y et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671-679
6. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826. doi:10.1056/NEJMoa041588
7. Ma XJ, Wang Z, Ryan PD et al (2004) A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5:607-616. doi:10.1016/j.ccr.2004.05.015
8. Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node- positive breast cancer patients: the PACS01 trial. J Clin Oncol 24:5664-5671. doi:10.1200/JCO.2006.07. 3916
9. Campone M, Campion L, Roche H et al (2008) Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen. Breast Cancer Res Treat 109:491-501. doi:10.1007/s10549-007-9673-x
10. Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393-10398. doi:10.1073/pnas.1732912100
11. Sotiriou C, Wirapati P, Loi S et al (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272
12. Pawitan Y, Bjohle J, Amler L et al (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7:R953-R964. doi:10.1186/bcr1325
13. Ivshina AV, George J, Senko O et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292-10301. doi:10.1158/0008-5472.CAN-05-4414
14. Chirgwin JM, Przybyla AE, MacDonald RJ et al (1979) Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299. doi:10.1021/bi00591a005
15. Magrangeas F, Nasser V, Avet-Loiseau H et al (2003) Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 101:4998-5006. doi:10.1182/blood-2002-11-3385
16. Decaux O, Lode L, Magrangeas F et al (2008) Prediction of survival in multiple myeloma based on gene-expression profiles revealed cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients. J Clin Oncol 26:4798-4805. doi:10.1200/JCO. 2007.13.8545
17. Heagerty PJ, Lumley T, Pepe MS (2000) Time-dependent ROC curves for recurrence and 15-survival data and a diagnostic marker. Biometrics 56:337-344. doi:10.1111/j.0006-341X.2000. 00337.x
18. Dupuy A, Simon RM (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99:147-157. doi:10.1093/jnci/djk018
19. Simon R (2005) Roadmap for developing and validating thera-peutically relevant genomic classifiers. J Clin Oncol 23:7332-7341. doi:10.1200/JCO.2005. 02.8712
20. Tinker AV, Boussioutas A, Bowtell DDL (2006) The challenges of gene expression microarrays for the study of human cancer. Cancer Cell 9:333-339. doi:10.1016/j.ccr.2006.05.001
21. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728. doi:10.1200/JCO.2007.15.1068
22. Habel LA, Shak S, Jacobs MK et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25. doi:10.1186/bcr1412
23. Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277. doi:10.1200/JCO.2005.02.0818
24. Fisher B, Dignam J, Wolmark N et al (1997) Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682. doi: 10.1093/jnci/89.22.1673
25. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, Estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734. doi:10.1200/JCO.2005.04.7985
26. Albain K, Barlow W, Shak S et al (2007) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814,INT0100). Presented at 30th Annual San Antonio Breast Cancer Symposium, San Antonio
27. Goldstein LJ, Gray R, Badve S et al (2008) Prognostic utility of the 21-gene assay in hormone receptor positive operable breast cancer compared with Adjuvant! an integrator of clinicopathologic and treatment information. J Clin Oncol 26:4063-4071
28. Van de Vijver MJ (2007) Gene-expression profiling and the future of adjuvant therapy. Oncologist 10(Suppl 2):30-34. doi: 10.1634/theoncologist.10- 90002-30
29. Pusztai L, Anderson K, Hess KR (2007) Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 13:6080-6086. doi:10.1158/1078-0432.CCR-07-0809